Thymosin alpha-1 treatment of cytomegalovirus infection with acute respiratory distress syndrome improved immune function and clinical outcomes, demonstrating its value for severe viral infections in immunocompromised patients.
Key findingThymosin alpha-1 enhanced immune function (CD4+/CD8+ T-cells, NK cells) and improved clinical outcomes in patients with CMV infection complicated by A
What the researchers found
Thymosin alpha-1 enhanced immune function (CD4+/CD8+ T-cells, NK cells) and improved clinical outcomes in patients with CMV infection complicated by ARDS, demonstrating clinical efficacy for severe opportunistic viral infections.
Why it matters
Relevant for thymosin-alpha-1, infection, immune-function.
How the study worked
clinical-trial study on thymosin-alpha-1, infection.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation.
Transplantation proceedings, 39(1), 115-9
Citation
Ji, S-M; Li, L-S; Sun, Q-Q; Chen, J-S; Sha, G-Z; Liu, Z-H. (2007). Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation.. Transplantation proceedings, 39(1), 115-9.